Article | July 13, 2021

Introduction To CAR T-Cell Therapy Part 1: Background & Current Development Landscape

By Ashley Herrick

t-cell attacking cancer 450x300

With the approvals of tisagenlecleucel (KYMRIAH™) and axicabtagene ciloleucel (YESCARTA™) last year, chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies.

What is CAR T-cell therapy?

CAR T-cell therapy involves re-engineering a patient’s own T-cells to recognize and eradicate cancer. These T-cells are genetically altered to express artificial receptors which enable the T-cells to bind to a specific antigen on the patient’s tumor cells and kill them. Unlike T-cell receptor-mediated immune reactions, CAR T-cell mediated immune reactions lead to direct recognition of extracellular tumor-associated antigens; however, immunogenicity can be challenging.

Continue reading to learn more about the advantages and challenges of CAR-T cell therapy as well as what the future may hold.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader